Frequently Asked Questions

Q: What does DVC do?
A: DVC manages product development programs for U.S. government agencies, and provides consulting, technical and project management services to companies in the biotechnology and pharmaceutical industries. DVC’s current portfolio includes vaccines and therapeutics to protect against emerging infectious diseases, biological and chemical warfare threat agents and seasonal and pandemic influenza.

Q: How is DVC involved in biodefense?
A: DVC was one of the first biodefense companies in Maryland. We were set up specifically to work on a biodefense contract for the Department of Defense. For more than 10 years now we’ve been developing a variety of biodefense vaccines and therapeutics. DVC’s Vaccinia Immune Globulin (VIGIV) was one of the first FDA-licensed biodefense products.

Q: How long has DVC been a CSC company?
A: Since 2004. DVC was formed in 1997 as a joint venture between DynCorp, a CSC Company, and Porton International Inc., a member of the Ipsen Group. In 2004, CSC acquired Porton’s interest in DVC and became the sole parent company. DVC is part of CSC's North American Public Sector, Civil and Health Services Group.

Q: How does DVC fit into CSC?
A: CSC brings a long and distinguished record of leadership in the healthcare market—nationally and worldwide—integrating commercial best practices with Government healthcare requirements, from development of healthcare systems to delivery of biodefense products. DVC’s specialty in program management for advanced development of biopharmaceutical products complements the extensive offerings of CSC and its Civil and Health Services division, providing customers with a fully integrated suite of services for protection of human health.

Q: What are some of DVC’s successes?
A: In our 10-year history, we’ve furthered the development of vaccines against smallpox and anthrax, and we’re still working on botulinum neurotoxin and plague vaccines for our DoD customers. We’ve also branched out into public health, adding vaccines against seasonal and pandemic influenza (better known as “bird flu”) to our pipeline in 2006. DVC has also advanced eight products into clinical trials in the last 10 years, including Phase 3 and overseas trials. In addition to DVC’s accomplishments, DVC works with 200+ world-class subcontractors, research centers and universities across the globe.

Q: What types of vaccine technology does DVC have experience with?
A: DVC’s experience includes:

• Alternative vaccine delivery systems
• Biological and chemical defense
• Biological therapeutics
• Emerging infectious diseases
• Live attenuated vaccines
• Recombinant vaccines
• Therapeutic polyclonal antibodies

Q: Does DVC specialize in certain elements of program management?
A: DVC has comprehensive experience in all facets of program management for government contracts. Programs managed by DVC typically include all or most of these areas:

• Biological and clinical data management
• Clinical trial management
• Contract life cycle management
• Manufacturing, testing and analytical services
• Nonclinical design and testing management
• Product and clinical quality assurance
• Product development strategy and management
• Regulatory oversight and strategy

Q: Are you looking for partners?
A: We are always looking for qualified subcontractors, manufacturers, CROs and research facilities. DVC conducts its procurement activities in accordance with numerous corporate and Federal procurement regulations, including the Federal Acquisition Regulation (FAR) and agency-specific FAR supplements.

Please note that DVC does not maintain laboratory or manufacturing facilities. We do not have a need for lab equipment.

Submit company information (name, address, point of contact, capabilities summary, etc.) using this form or by mail to:

DynPort Vaccine Company LLC, A CSC Company
c/o New Business
64 Thomas Johnson Drive
Frederick, MD 21702

Your information will be distributed to the appropriate DVC staff for review. This will alert DVC to the fact that it has a potential new vendor for your particular goods and/or services. DVC may then consider including your company in future solicitations, if appropriate. If deemed appropriate by DVC, we may invite you to conduct a capabilities presentation for applicable DVC scientific/technical/business personnel. We look forward to working with you!

Learn More

Download case studies about various DVC programs.

Read more about small business procurement at DVC.

Complete a supplier profile at CSC's Supplier Diversity site.

Members of the press: contact our Communications department for more information.